Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Cardiology PC

Neither a doctor nor a teaching hospital

Research payments

$162,319

166 payments

Through program year 2025, Cardiology PC is reported as receiving $162,319 in research payments, across 166 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $28,122 86
2024 Research $67,887 24
2023 Research $2,134 5
2022 Research $20,749 12
2021 Research $12,193 7
2020 Research $6,129 4
2019 Research $25,105 28

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $53,409 9 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $35,419 28 payments
  3. Moderna TX, Inc. $24,517 13 payments
  4. Edwards Lifesciences Corporation $14,067 11 payments
  5. Boston Scientific Corporation $13,761 15 payments
  6. Boehringer Ingelheim International GmbH $10,802 81 payments
  7. Abbott Laboratories $10,344 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. Obesity Long term safety in patients with CV risk $37,014 5 payments
  2. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $27,197 85 payments
  3. A Phase 1, Adaptative, Open-Label, Single Ascending Dose to Single-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 in Participants with Chronic Heart Failure $24,517 13 payments
  4. BAY94-8862 LCM HFmr/pEF (EF 40%) $16,641 13 payments
  5. Commence Study 2012-02 $14,067 11 payments
  6. Reduce HTN Reinforce $12,699 13 payments
  7. A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) $11,349 6 payments
  8. A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions. $8,594 7 payments
  9. BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti $7,429 9 payments
  10. Abbott Vascular / XIENCE $1,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record